RESEARCHER PROFILE
Dr Katharina Richter,
University of Adelaide
Filmed November 2023
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
Katharina champions gender diversity, serving as a role model for aspiring female leaders. Her international impact is undeniable, as she elevates Australian MedTech on the global stage through panels, collaborations and media engagements. Katharina’s leadership extends to various committees and organisations, where she nurtures the next generation of MedTech
leaders through mentorship and career-development initiatives. Her remarkable journey showcases her as a true pioneer, leaving an indelible mark on both the MedTech industry and the advancement of women within it.
You Might also like
-
Prescribing exercise to regional population with cardiovascular disease & diabetes
Associate Professor Gordon’s research is aimed at determining the optimal methods of prescribing and implementing exercise as part of the health care plan for people with cardiovascular disease and diabetes. Specifically, he is leading work to determine if and how the components of exercise can be considered as a whole for prescribing exercise to generate health benefits. This is important to overcome the series of barriers that people living in rural and regional areas experience when trying to become active.
-
Dr Jade Murray
DR JADE MURRAY, POSTDOCTORAL RESEARCH FELLOW
TURNER INSTITUTE FOR BRAIN AND MENTAL HEALTH, MONASH UNIVERSITY
VICTORIA, AUSTRALIA -
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.